News Release

For Immediate Release

BioCurex Completes Private Placement Financing

RICHMOND, British Columbia, Sept. 17, 2009 (GLOBE NEWSWIRE) -- Whispering Oaks International, Inc., d/b/a BioCurex (OTCBB:BOCX - News) announced today that it has completed a private placement financing in which it sold promissory notes in the aggregate principal amount of $450,000 and 6,428,578 shares of its common stock for an aggregate purchase price of $450,000. After deducting a commission of $55,500 payable to the placement agent in connection with the sale, the Company received net proceeds of $394,500.

The promissory notes bear interest at a rate of 10% per annum. Both interest and principal are payable on August 31, 2010. However, if the Company sells any capital stock and receives gross proceeds of at least $3 million from such sale prior to August 31, 2010, it must prepay the principal under the notes from such proceeds.

Dr. Ricardo Moro, Chief Executive Officer of BioCurex, stated: "Having concluded a three year 'standstill' arrangement with our secured note holders (as previously announced), we were able to successfully complete this financing. The net proceeds from the sale of these securities, which have already been released from escrow, will be used to fund our operations and enable us to pursue other financing alternatives."

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements see:  http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt).

The cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

To read more about the Company, please visit the News section in our web site (www.biocurex.com).

Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are “forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
Contact:
Ricardo Moro
BioCurex, Inc.
Tel: (604) 207-9150